Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies.
JW Carlisle, RD Harvey - American Society of Clinical Oncology …, 2021 - europepmc.org
The number of therapeutic options available for patients with advanced non-small-cell lung
cancer has been led by deeper understanding of molecular drivers, immune function, and …
cancer has been led by deeper understanding of molecular drivers, immune function, and …
HER2 alterations in non-small-cell lung cancer–Druggable or undruggable?
SK Bondili, R Nandhana, V Noronha… - Cancer Research …, 2021 - journals.lww.com
Figure 1: Response to various lines of therapy as shown by computed tomography scans.(a)
Baseline,(b) Partial response after four cycles of pemetrexed+ carboplatin+ atezolizumab,(c) …
Baseline,(b) Partial response after four cycles of pemetrexed+ carboplatin+ atezolizumab,(c) …
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
R Liu, K Ota, E Iwama, Y Yoneshima, K Tanaka… - Lung Cancer, 2021 - Elsevier
Objectives The epidermal growth factor receptor (EGFR, also known as Her1) is a member
of the human epidermal growth factor receptor (HER) family of proteins and a target of …
of the human epidermal growth factor receptor (HER) family of proteins and a target of …
Different conformations of EGF-induced receptor dimers involved in signaling and internalization
J Haubrich, JM Zwier, F Charrier-Savournin, L Prézeau… - bioRxiv, 2022 - biorxiv.org
The structural basis of the activation of EGF receptors (EGFR) is still a matter of debate
despite the importance of this target in cancer treatment. Whether agonists induce dimer …
despite the importance of this target in cancer treatment. Whether agonists induce dimer …
Testing for genomic biomarkers in non-small-cell lung cancer
OG Shutkever, P Bennett, DA Moore - Diagnostic Histopathology, 2024 - Elsevier
The number of targeted therapies licenced for non-small cell lung cancer (NSCLC) has
increased substantially in recent years, resulting in a major increase in demand for genomic …
increased substantially in recent years, resulting in a major increase in demand for genomic …
Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus …
SY Lin, YH Wang, CY Hsu, YJ Chen, CR Lai… - …, 2021 - Wiley Online Library
Aims The aim of this study was to evaluate human epidermal growth factor receptor 2
(HER2) immunohistochemistry (IHC) in ovarian clear cell carcinoma (OCCC) by using two …
(HER2) immunohistochemistry (IHC) in ovarian clear cell carcinoma (OCCC) by using two …
[图书][B] Targeting Oncogenic Driver Mutations in Lung Cancer
The recent advances in the field of molecular diagnostic techniques have led to the
identification of targetable alterations prompting a paradigm shift in the management of non …
identification of targetable alterations prompting a paradigm shift in the management of non …
Erb-b2 Receptor Tyrosine Kinase 2 Interaction with Growth Factor Receptor Bound Protein 7 Acts as a Molecular Switch to Activate Non-Small Cell Lung Cancer: An …
Background: The progression and metastasis of non small cell lung cancer (NSCLC) are
considered a very complex process as it involves aberrations of multiple genes and cellular …
considered a very complex process as it involves aberrations of multiple genes and cellular …
Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
Background Discordant results exist about the role of human epidermal growth factor
receptor 2 (HER2) overexpression and/or HER2 amplification in lung adenocarcinoma. We …
receptor 2 (HER2) overexpression and/or HER2 amplification in lung adenocarcinoma. We …
Drug Resistance in Lung Cancer
C Colarusso, M Terlizzi, A Pinto, R Sorrentino - 2022 - Springer
Lung cancer incidence is very high worldwide and nowadays represents the second most
diagnosed cancer and the leading cause of cancer-related death. Treatment options for lung …
diagnosed cancer and the leading cause of cancer-related death. Treatment options for lung …